Vaskulitiden

Zusammenfassung

Die primär systemischen Vaskulitiden (PSV) gehören zu den Autoimmunerkrankungen mit der ungünstigsten Prognose; sowohl quoad vitam als auch in Bezug auf Organschäden und Verlust an Lebensqualität. In Verbindung mit ihrer relativen Seltenheit im Vergleich zu anderen rheumatischen Erkrankungen sind sie daher a priori als schwere Verlaufsformen rheumatischer Erkrankungen zu betrachten. Innerhalb der primär systemischen Vaskulitiden lassen sich dennoch wiederum Verläufe definieren, die besonders schwerwiegend, d. h. mit schlechter Prognose assoziiert sind.

Summary

Primary systemic vasculitides belong to the autoimmune diseases with the worst prognosis, with respect to survival, organ damage and quality of life. In conjunction with their rarity they should a priori be regarded as severe rheumatic conditions. Despite that, there are specific constellations and states within the group of primary vasculitides which can be defined as particularly severe courses.

Schlüsselwörter

Vaskulitiden - Riesenzellarteriitis - ANCA-assoziierte Vaskulitiden

Keywords

Vasculitides - giant cell arteritis - ANCA associated vasculitides

• Literatur

• 1 Little MA, Nightingale P, Verburgh CA. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69: 1036-1043.
• 2 Toledano E, Candelas G, Rosales Z. et al. A meta-analysis of mortality in rheumatic diseases. Rheumatol Clin 2012; 8: 334-341.
• 3 Mukhtyar C, Guillevin L, Cid MC. et al. EULARrecommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317.
• 4 Mukhtyar C, Guillevin L, Cid MC. et al. EULARrecommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-323.
• 5 Holle JU, Gross WL, Latza U. et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011; 63: 257-266.
• 6 Moosig F, Bremer JP, Hellmich B. et al. Avasculitiscentre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72: 1011-1017.
• 7 Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 2013; 25: 3-9.
• 8 Mahr AD, Jover JA, Spiera RF. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-2797.
• 9 Loock J, Henes J, Kötter I. et al. Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 2012; 30 (01) (Suppl. 70) S70-S76.
• 10 Unizony S, Arias-Urdaneta L, Miloslavsky E. et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasuarteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012; 64: 1720-1729.
• 11 García-Martínez A, Arguis P, Prieto-González S. et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis. 2013 [Epub ahead of print]
• 12 Guillevin L, Lhote F, Gayraud M. et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 17-28.
• 13 Guillevin L, Pagnoux C, Seror R. et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90: 19-27.
• 14 Holle JU, Gross WL, Holl-Ulrich K. et al. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage?. Ann Rheum Dis 2010; 69: 1934-1939.
• 15 Mukhtyar C, Lee R, Brown D. et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68: 1827-1832.
• 16 Hellmich B, Flossmann O, Gross WL. et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007; 66: 605-617.
• 17 Holle JU. ANCA-associated vasculitis. Z Rheumatol 2013; 72: 445-456.
• 18 Tzelepis GE, Kokosi M, Tzioufas A. et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010; 36: 116-121.
• 19 Bremer JP, Csernok E, Holle J. et al. Getting rid of MPO-ANCA: a matter of disease subtype. Rheumatology (Oxford) 2013; 52: 752-754.
• 20 Valent P, Klion AD, Horny HP. et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130: 607-612.
• 21 Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?. Arthritis Res Ther 2009; 11: 253.